Braveheart Bio, Inc.
BRVE- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
Follow BRVE
Alert me
Braveheart Bio, Inc. (BRVE) Return on invested capital
Braveheart Bio, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −28.7%, down 28.7 percentage points from fiscal 2025 (0.00%). That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ZYME Zymeworks Inc. compare | 17.5% |
| FTRE Fortrea Holdings Inc. compare | 0.59% |
| COAG Hemab Therapeutics Holdings, Inc. compare | 0.00% |
| QURE uniQure N.V. compare | 0.00% |
| ZBIO Zenas BioPharma, Inc. compare | 0.00% |
| BRVE Braveheart Bio, Inc. | −28.7% |
| AGIO Agios Pharmaceuticals, Inc. compare | −75.0% |
| TRVI Trevi Therapeutics, Inc. compare | −1,309.1% |
| LYCA Lycia Therapeutics Inc. compare | — |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)